Whitehawk Therapeutics (WHWK) Restructuring Costs (2019 - 2024)
Whitehawk Therapeutics (WHWK) posted quarterly Restructuring Costs of $2.6 million for Q3 2024, up 6897.22% quarter-over-quarter from -$38810.0 in Q3 2019.
Powered by 
Analysis
Whitehawk Therapeutics (WHWK) Restructuring Costs (2019 - 2024) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Restructuring Costs for 2 consecutive years, with $2.6 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Restructuring Costs changed N/A year-over-year to $2.6 million; the TTM figure through Dec 2025 stood at $2.6 million (changed 0.0% YoY), while the FY2024 annual figure was $2.6 million, changed N/A from the prior year.
- Restructuring Costs climbed to $2.6 million in Q3 2024 per WHWK's latest filing, from -$38810.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $2.6 million in Q3 2024 and bottomed at $2.6 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Whitehawk Therapeutics | 377.13 Mn | 377.13 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 2.64 Mn |
| Mar 31, 2021 | 1.24 Mn |
| Dec 31, 2019 | 987,211.00 |
| Sep 30, 2019 | -38,810.00 |
| Jun 30, 2019 | 915,094.00 |